Introduction: Although SBS has been recognized as a rare disease, registries have not been developed in all countries. RESTORE project is a prospective, observational, epidemiological, multicenter registry to compile and assess the epidemiology, natural history, current available therapies and their results in SBS patients. Methods: Adult patients with III-IF due to SBS were included and followed at weeks 4, 8, 12, 20, 24 and yearly thereafter in all centers that obtained the Institutional Review Board and Ethical approval. Demographic variables, etiology, anatomy type (AT), intestinal length (IL), parenteral nutrition (PN) requirements and IF related complications, among others were analyzed. Patients were divided according to the use of enterohormone therapy as Never Treated group (NTg) and Ever Treated group (ETg) Results: From June 2017 to June 2020, 8/12 centers enrolled a total of 61 adult patients, 4 were excluded (2 loss of follow up and 2 incomplete written consent); 45 in the NTg and 12 in the ETg. The mean age was 49.7±17.4 years and 52.6% were female. The main cause of SBS was post-surgical complications (29.8%). At enrollment 41 patients had AT1, 11 type 2, and 5 type 3. The mean IL was 64.8± 45.7cm in NTg vs 39.4±29.1cm in ETg. PN requirements were higher in the NTg. Statistical differences were observed in volume (p:0.03) and Kcal (p:0.03) reduction during the follow up in the ETg. Autologous Gastrointestinal Reconstruction Surgery was performed in 30 patients in the NTg, 21 before enrollment and nine during the follow up. All patients in ETg received AGIRS prior to enrollment. Ten patients from NTg and 2 from ETg reached intestinal sufficiency and 17 had >20% of PN Kcal or volume reduction.In the ETg, 11/12 patients received semisynthetic Glucagon Like Peptide 2 and one obese patient received semisynthetic Glucagon Like Peptide 1. Conclusions: RESTORE demonstrated the benefit of having a national registry for III-IF patients in Argentina allowing us to better understand not only the epidemiology of the disease but also its natural course, as well as the results of different current available therapeutic options to continue improving the management of patients suffering from SBS.